Bristol Myers Squibb Expands AI Capabilities Using Nvidia Systems
Bristol Myers Squibb has enhanced its artificial intelligence capabilities by integrating Nvidia’s DGX SuperPOD and Vera Rubin NVL72 systems into its operations. The move is expected to improve the company's drug development processes through advanced supercomputing infrastructure.
Topics: artificial intelligence pharmaceuticals supercomputing